Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Background</h3><p>Pancreatic ductal adenocarcinoma (PDAC) exhibits the poorest prognosis of all solid tumors with a 5‐year survival rate of less than 10% and a median survival of 6 months after diagnosis. Numerous targeted agents have been developed and evaluated to improve the survival benefit in patients with PDAC. Unfortunately, most agents have been proven futile mainly owing to the dense stroma and the sophisticated signaling pathways of PDAC. Here, we show the potent effectiveness of Aptamer‐SH2 superbinder‐(Arg)9 conjugate on the treatment of PDAC. In this conjugate, DNA aptamer selected against PDAC cell line confers the function of specifically recognizing and binding to the PDAC cells and activated pancreatic stellate cells (PSCs) in stroma; cell penetrating peptide (Arg)9 facilitates the intracellular delivery of fused proteins; SH2 superbinder conducts the drastic blockade of multiple phosphotyrosines (pY)‐based signaling pathways in tumor cells.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Methods</h3><p>PDAC‐associated pY were reanalyzed by bioinformatics screen. XQ‐2d and SH2 superbinder‐(Arg)9 were crosslinked with BMH to form XQ‐2d‐SH2 CM‐(Arg)9 conjugate. Immunofluorescence was utilized to assess the potency of the conjugate entering cells. MTT and wound healing assays were performed to evaluate the proliferation or migration of PANC‐1 and BxPC‐3 cells, respectively. Western blot and Pulldown assays revealed that conjugate influenced several pY‐based signaling pathways. Tumor‐bearing mice were used to validate XQ‐2d‐SH2 CM‐(Arg)9, which restrained the growth and metastasis of cancer cells.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Results</h3><p>XQ‐2d‐His‐SH2 CM‐(Arg)9 conjugate restrained proliferation, invasion, and metastasis of PDAC cells with potent efficacy via blocking the activity of several pY‐related signaling cascades. XQ‐2d‐His‐SH2 CM‐(Arg)9 could eliminate the dense stroma of PDAC and then arrive at tumor tissues.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusions</h3><p>XQ‐2d‐SH2 CM‐(Arg)9 conjugate may efficiently destroy the pancreatic stroma and show potent antitumor efficacy with minimal toxic effect by regulating tumor cell proliferation and metastasis in vitro and in vivo, which makes it to be a promising targeted therapy of PDAC.</p></section>

What problem does this paper attempt to address?

### Problems the paper attempts to solve This paper aims to solve several key problems in the treatment of pancreatic ductal adenocarcinoma (PDAC): 1. **Low survival rate**: PDAC is one of the cancers with the worst prognosis among all solid tumors. The 5 - year survival rate is less than 10%, and the median survival time after diagnosis is only 6 months. 2. **Limitations of existing treatment methods**: Although a variety of targeted drugs have been developed and evaluated to improve the survival rate of PDAC patients, most drugs are ineffective due to the dense stroma of the tumor and complex signaling pathways. 3. **Abnormal activation of tyrosine phosphorylation**: Tyrosine phosphorylation plays a key role in the development of PDAC. The abnormal activation of many receptor tyrosine kinases (RTKs) and cytoplasmic tyrosine kinases (CTKs) leads to signal pathway disorders, thereby promoting tumor proliferation, invasion and metastasis. 4. **Necessity of multi - target inhibition**: Single - target tyrosine kinase inhibitors (TKIs) or multi - kinase inhibitors have limited effects in blocking multiple RTKs and CTKs in complex signal cascades, and new multi - target inhibition strategies are required. ### Solutions To overcome the above problems, this study proposes a targeted treatment strategy based on Aptamer - SH2 superbinder - (Arg)9. Specifically: 1. **Aptamer**: Select the DNA aptamer XQ - 2d against PDAC cell lines, which can specifically recognize and bind to transferrin receptor 1 (TfR1, CD71) in PDAC cells and activated pancreatic stellate cells (PSCs). 2. **SH2 superbinder**: The SH2 superbinder has a stronger binding ability to tyrosine - phosphorylated residues (pY) and can effectively capture multiple pY peptides, blocking multiple pY - dependent signaling pathways. 3. **Cell Penetrating Peptide (CPP)**: (Arg)9, as a cell - penetrating peptide, helps the fusion protein enter the cell interior. By combining these three components, the formed XQ - 2d - His - SH2 CM - (Arg)9 conjugate can efficiently disrupt the dense stroma of PDAC in vivo and in vitro experiments, inhibit the proliferation, invasion and metastasis of tumor cells, and has less toxicity to normal cells, showing potential for clinical application.

Aptamer‐SH2 superbinder‐based targeted therapy for pancreatic ductal adenocarcinoma

Targeting pancreatic cancer cells by a novel hydroxamate-based histone deacetylase (HDAC) inhibitor ST-3595

The PAK Inhibitor PF-3758309 Promotes the Inhibitory Effects of Multiple Chemotherapeutic Reagents on Patient-Derived Pancreatic Cancer Cell Lines

Inhibition of P21 Activated Kinase Enhances Tumour Immune Response and Sensitizes Pancreatic Cancer to Gemcitabine

PAK Inhibition by PF-3758309 Enhanced the Sensitivity of Multiple Chemotherapeutic Reagents in Patient-Derived Pancreatic Cancer Cell Lines.

Development Of A Novel Ron Receptor Targeted Antibody-Drug Conjugates Using Cysteine Bridging Technology For Potential Treatment Of Pancreatic Cancer

Development of A Novel RON Targeted Antibody‐Drug Conjugates Using Cysteine Bridging Technology for Potential Treatment of Pancreatic Cancer

Targeting X-linked Inhibitor of Apoptosis Protein Inhibits Pancreatic Cancer Cell Growth Through P-Akt Depletion.

Anti-tumor activity of antibody drug conjugate targeting aspartate-β-hydroxylase in pancreatic ductal adenocarcinoma

Sequentially Triggered Nanoparticles with Tumor Penetration and Intelligent Drug Release for Pancreatic Cancer Therapy

Complexation of drug and hapten-conjugated aptamer with universal hapten antibody for pancreatic cancer treatment

Plectin-1-targeted recognition for enhancing comprehensive therapy in pancreatic ductal adenocarcinoma

Tumor-Specific Delivery of 5-Fluorouracil–Incorporated Epidermal Growth Factor Receptor–Targeted Aptamers as an Efficient Treatment in Pancreatic Ductal Adenocarcinoma Models

Advances in targeted therapy for pancreatic cancer

Development of a novel multi-functional integrated bioconjugate effectively targeting K-Ras mutant pancreatic cancer

Aptamer-drug conjugates-loaded bacteria for pancreatic cancer synergistic therapy

Targeted delivery of CEBPA-saRNA for the treatment of pancreatic ductal adenocarcinoma by transferrin receptor aptamer decorated tetrahedral framework nucleic acid

Penetrating Micelle for Reversing Immunosuppression and Drug Resistance in Pancreatic Cancer Treatment

Bone marrow mesenchymal stem cells-derived exosomes for penetrating and targeted chemotherapy of pancreatic cancer

Targeted delivery of chemotherapy using HSP90 inhibitor drug conjugates is highly active against pancreatic cancer models

Inhibition of Epithelial‐to‐mesenchymal Transition Augments Antitumor Efficacy of Nanotherapeutics in Pancreatic Ductal Adenocarcinoma